The aim of this phase II trial is to assess progress-free survival, local control, overall survival, safety and tolerability of SBRT to treat patients with oligometastases in esophageal squamous cell carcinoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
34
Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
Fudan Universtiy Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Progression-free survival
progression-free survival will be measured as time to either progression or death
Time frame: The survival time from the date each patient enrolled to the date of progression or date of death from any cause, whichever came first, assessed up to 5 years
Local control
Local control will be measured as time to local recurrence
Time frame: the time from the date each patient enrolled to the date of local failure or the last follow-up, assessed up to 5 years.
overall survival
Overall survival will be measured as time until death from any cause
Time frame: The survival time from the date each patient enrolled to the date of death or the last follow-up, assessed up to 5 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.